The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jul. 14, 2015

Filed:

Jun. 22, 2011
Applicants:

Bernhard Palsson, San Diego, CA (US);

Vasiliy A. Portnoy, San Diego, CA (US);

Inventors:

Bernhard Palsson, San Diego, CA (US);

Vasiliy A. Portnoy, San Diego, CA (US);

Assignee:
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C12P 7/18 (2006.01); C12P 13/04 (2006.01); C12N 15/70 (2006.01); C12P 7/56 (2006.01); C12N 9/02 (2006.01);
U.S. Cl.
CPC ...
C12N 15/70 (2013.01); C12N 9/0053 (2013.01); C12P 7/18 (2013.01); C12P 7/56 (2013.01); C12P 13/04 (2013.01);
Abstract

The invention provides transgeniccells comprising a mutation in cydAB gene, and/or cyoABCD gene, and/or cbdAB gene, and/or ygiN gene, wherein the mutation reduces (preferably, but not necessarily, by 100%) the cytochrome oxydase activity of a protein encoded by cydAB gene, and/or cyoABCD gene, and/or cbdAB gene, and/or ygiN gene. In a preferred embodiment, the mutation is a deletion of the cydAB gene, cyoABCD gene, and cbdAB gene. In another embodiment, the mutation is a deletion of the cydAB gene, cyoABCD gene, cbdAB gene, and ygiN gene. In another embodiment, the transgeniccell, which comprises a deletion of cydAB gene, and/or cyoABCD gene, and/or cbdAB gene, and/or ygiN gene a) has substantially the same level of growth in oxic conditions as the level of growth in anoxic conditions ofthat lacks said deletion of cydAB gene, and/or cyoABCD gene, and/or cbdAB gene, and/or ygiN gene, and b) is capable of converting glucose to D-lactate and/or amino acid and/or 2,3-butanediol (2,3-BDO) under one or both of oxic conditions and anoxic conditions.


Find Patent Forward Citations

Loading…